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Centro de Referencia para Lactobacilos (CERELA-CONICET), San Miguel de Tucumán, Argentinaa; INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR
1319 Micalis, Jouy-en-Josas, Franceb; AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, Francec; Cátedra de Metodología de la Investigación Científica, Facultad de
Medicina, Universidad Nacional de Tucumán, San Miguel de Tucumán, Argentinad
The aims of this study were to develop strains of lactic acid bacteria (LAB) having both immunomodulatory and antioxidant
properties and to evaluate their anti-inflammatory effects both in vitro, in different cellular models, and in vivo, in a mouse
model of colitis. Different Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus strains were cocultured
with primary cultures of mononuclear cells. Analysis of the pro- and anti-inflammatory cytokines secreted by these cells after
coincubation with candidate bacteria revealed that L. delbrueckii subsp. bulgaricus CRL 864 and S. thermophilus CRL 807 dis-
play the highest anti-inflammatory profiles in vitro. Moreover, these results were confirmed in vivo by the determination of the
cytokine profiles in large intestine samples of mice fed with these strains. S. thermophilus CRL 807 was then transformed with
two different plasmids harboring the genes encoding catalase (CAT) or superoxide dismutase (SOD) antioxidant enzymes, and
the anti-inflammatory effects of recombinant streptococci were evaluated in a mouse model of colitis induced by trinitrobenze-
nesulfonic acid (TNBS). Our results showed a decrease in weight loss, lower liver microbial translocation, lower macroscopic
and microscopic damage scores, and modulation of the cytokine production in the large intestines of mice treated with either
CAT- or SOD-producing streptococci compared to those in mice treated with the wild-type strain or control mice without any
treatment. Furthermore, the greatest anti-inflammatory activity was observed in mice receiving a mixture of both CAT- and
SOD-producing streptococci. The addition of L. delbrueckii subsp. bulgaricus CRL 864 to this mixture did not improve their
beneficial effects. These findings show that genetically engineering a candidate bacterium (e.g., S. thermophilus CRL 807) with
intrinsic immunomodulatory properties by introducing a gene expressing an antioxidant enzyme enhances its anti-inflamma-
tory activities.
Inflammatory bowel disease (IBD) is a group of chronic inflam-matory disorders of the gut with a substantial socioeconomic
impact worldwide (1). The two major forms of IBD are Crohn’s
disease (CD) and ulcerative colitis (UC), which are characterized
by an uncontrolled inflammatory response to luminal content
and which differ mostly by the region of the gut where inflamma-
tion progresses and the depth of inflammatory damage. Conven-
tional IBD therapy with antibiotics and corticosteroids is often
associated with negative side effects. The difficulty in developing
new therapeutic options for the treatment of IBD is thus a major
challenge, from a medical and patient care point of view and in
regard to economic and social aspects as well.
Currently, numerous studies have suggested possible health
benefits associated with the consumption of probiotics (“live mi-
croorganisms which when administered in adequate amounts
confer a health benefit on the host” [2]). In particular, probiotics
represent a potential alternative for IBD treatment due to their
active role in enhancing the intestinal barrier function, by either
modifying the intestinal microbiota or modulating the host im-
mune response (3, 4). Notably, it has been previously shown that
a yogurt prepared with a pool of candidate probiotic strains of
Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus ther-
mophilus from the Culture Collection of the Centro de Referencia
para Lactobacilos (CERELA) (San Miguel de Tucumán, Argen-
tina) diminished the severity of inflammation in a mouse model of
chemically induced colitis by modulating the immune response of
the host, mainly due to an increase in the number of interleu-
kin-10 (IL-10)-producing cells at the intestinal level with a signif-
icant decrease of IL-17 and IL-12 production (5, 6). More recently,
it has been described that genetically engineered lactic acid bacte-
ria (LAB) producing antioxidant enzymes such as catalase (CAT)
or superoxide dismutase (SOD) were able to reduce the inflam-
mation in different murine models of chemically induced colitis
through a different mechanism, which was a reduction of reactive
oxygen species (ROS) levels in the gut (7–10). From this perspec-
tive, we hypothesized that the expression of such antioxidant en-
zymes in LAB strains with proven intrinsic immunomodulatory
properties could enhance their anti-inflammatory activities.
Therefore, the aims of this study were to construct a novel anti-
inflammatory LAB strain with immunomodulating as well as an-
tioxidant properties and to evaluate its anti-inflammatory activity
in vitro and in vivo.
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Bacterial strains and growth conditions. L. delbrueckii subsp. bulgaricus
(CRL 861, 863, 864, 866, 869, 871, 872 and 887) and S. thermophilus (CRL
806 and 807) strains from the CERELA Culture Collection (Tucumán,
Argentina) were grown for 16 h at 37°C without agitation in MRS (Brita-
nia, Buenos Aires, Argentina) and LAPTg (1% glucose, 1.5% peptone, 1%
tryptone, 1% yeast extract, and 0.1% Tween 80) medium, respectively.
For fermented milk preparation, bacterial strains were grown over-
night in 5 ml reconstituted sterile (autoclaved at 110 to 115°C for 10 min)
nonfat milk (Milkaut, Argentina). These cultures were used to inoculate
the milk with either L. delbrueckii subsp. bulgaricus or S. thermophilus
strains at a concentration of 1% (vol/vol) and incubated without agitation
for 16 h at 37°C. Yogurt was prepared freshly by inoculating milk with the
pools of lactobacilli and streptococci (grown in milk) at a concentration of
0.5% (vol/vol) each and incubated without agitation for 16 h at 37°C.
In vitro assays using different cellular models. Commercial periph-
eral blood mononuclear cells (PBMC) from healthy donors were obtained
from StemCell Technologies (Grenoble, France) and grown in RPMI 1640
medium (Sigma, St. Louis, MO, USA) with 1% L-glutamine and 10%
heat-inactivated fetal bovine serum (FBS) in a humidified 10% CO2 at-
mosphere at 37°C (32). Isolation of Peyer’s patch mononuclear cells
(PPMC) from healthy mice was performed as previously described (11).
For PBMC, cells were spread in 24-well culture plates at 1  106 cells/
well. The LAB strains were grown in MRS overnight (16 h), and then the
cultures were diluted to an optical density (OD) at 600 nm of 0.3, washed
with 0.01 M phosphate-buffered saline (PBS) (pH 7.4), resuspended in
PBS, and added at a multiplicity of infection (MOI) of 1:102 (cells/bacte-
ria). Plates were coincubated for 24 h at 37°C in 10% CO2 and samples
collected for IL-10 and IL-12 determination by enzyme-linked immu-
nosorbent assay (ELISA) (MABTECH AB, Sweden). PBS without bacteria
was used as negative control.
For PPMC isolated from mice, cells were spread in 6-well culture
plates at 2  106 cells/well. Bacteria were grown in milk because the in vivo
assay would be performed with fermented milk. Bacterial counts were
determined in MRS agar plates, and PPMC were cocultured in RPMI 1640
for 24 h at 37°C with 20 l of each individual strain grown in milk for 16
h (1  109 CFU/ml; MOI of 1:10 [cells/bacteria]) or with noninoculated
milk or yogurt as negative and positive controls, respectively. IL-10 and
gamma interferon (IFN-) concentrations from PPMC supernatants
were measured using BD OptEIA cytokine ELISA sets (BD Bioscience, San
Diego, CA, USA).
In vivo evaluation of the intestinal cytokine profiles induced by the
administration of selected LAB to healthy mice. BALB/c mice (female, 5
weeks old, weighing 20 to 25 g) were obtained from the inbred animal
facilities at CERELA. All animal protocols were approved by the Animal
Protection Committee of CERELA (CRL-BIOT-LT-2010/1A), and all ex-
periments comply with the current laws of Argentina.
Groups of mice (n  5) were fed for 10 days ad libitum with either
unfermented milk or milk fermented by L. delbrueckii subsp. bulgaricus
CRL 864 or S. thermophilus CRL 807. The mice were then sacrificed, and
the intestinal contents were collected from their large intestines with 1 ml
PBS and immediately centrifuged at 5,000  g for 15 min at 4°C. The
supernatants were recovered and stored at 20°C until determination of
IFN- and IL-10 concentrations using BD OptEIA cytokine ELISA sets
(BD Bioscience).
The large intestines and ceca were removed and prepared for histolog-
ical evaluation using standard methods. Cytokine-positive cells were de-
tected by indirect immunofluorescence on large intestine tissue slides,
using a previously described technique (12). Rabbit anti-mouse IL-10
(ProSci Inc., Poway, CA, USA) or goat anti-mouse IL-17 (BD Bioscience,
San Diego, CA, USA) polyclonal antibodies were used as primary antibod-
ies, and goat anti-rabbit or rabbit anti-goat antibodies conjugated with
fluorescein isothiocyanate (FITC) (Jackson Immuno Research Laborato-
ries Inc., West Grove, PA, USA) were used as secondary antibodies. The
number of fluorescent cells was counted by two scientists (two individual
blinded counts per sample), and the results were expressed as the number
of positive cells for each cytokine in 10 fields of vision as seen at a magni-
fication of 1,000 using a fluorescence light microscope (Carl Zeiss, Ger-
many).
DNA manipulations. The plasmids used in this study (pIL253-sodA
and pIL253-mnkat) were isolated from the Lactobacillus casei BL23 strain
harboring the vector of interest (BL23:SOD and BL23:CAT, respectively)
(13). Briefly, lysis was performed by incubating bacterial pellets with 10
mg/ml lysozyme for 1 h at 37°C. After this step, the Accuprep Plasmid
Mini Extraction kit (Bioneer, Daejeon, South Korea) was used according
to manufacturer=s instructions. S. thermophilus strain CRL 807 was trans-
formed with either pIL253-sodA or pIL253-mnkat plasmid using a mod-
ified electroporation protocol (14). Briefly, in order to obtain competent
cells, this strain was grown in 5 ml of M17 medium (Difco, Detroit, MI,
USA) containing 1% glucose (GM17) for 16 h at 37°C. This culture was
diluted in 200 ml of GM17 supplemented with 1% glycine and grown at
37°C to an optical density (OD) at 600 nm of 0.4 to 0.6, and the cells were
harvested by centrifugation at 5,000  g (4°C). After 4 washes with ice-
cold 0.5 M sucrose containing 10% glycerol, the cells were finally resus-
pended in 1 ml of cold 30% polyethylene glycol (PEG) 3000 –10% glycerol
and stored in aliquots (100 l) at 80°C until further use. For electropo-
ration, 100 l was thawed on ice, mixed with 100 to 200 ng of plasmid, and
then transferred to an ice-cooled electroporation cuvette. The sample was
subjected to a 2.5-kV, 200-, 25-F electric pulse in a 0.2-cm cuvette by
using a Gene Pulser and a Pulse Controller apparatus (Bio-Rad, Rich-
mond, CA, USA). Transformants were selected based on the antibiotic
resistance on GM17 agar plates containing 2.5 g/ml erythromycin as
described previously (15) and then transferred to fresh broth GM17 me-
dium with 5 g/ml erythromycin in order to confirm the acquired resis-
tance in the recombinant strains. Plasmid DNA was extracted as described
above and characterized by enzymatic digestion. Recombinant S. thermo-
philus CRL 807 strains harboring either pIL253-mnkat or pIL253-sodA
plasmid were named S. thermophilus CRL 807:CAT and CRL 807:SOD,
respectively. Plasmid stability was evaluated by growing the transformants
without a pressure selection (i.e., use of antibiotics) for 200 generations,
and we confirmed the presence of kat and sod genes by PCR. We also
confirmed their identity by restriction enzyme analysis. The same proto-
col was used to detect the presence of plasmids after milk fermentation.
Characterization of recombinant LAB strains. Transformant candi-
dates were confirmed by PCR using previously described specific primers
for the mnkat (16) or sodA (10) gene and by detection of CAT and SOD
activities. Cell pellets resuspended in MilliQ water were used as templates
for amplification. PCR was performed using Taq DNA polymerase (Invit-
rogen Life Technologies, São Paulo, Brazil) according to the manufactur-
er’s instructions.
In order to detect enzyme production, cultures of recombinant LAB
strains grown overnight in medium or in milk were inoculated at a 1:50
dilution in 10 ml fresh medium supplemented with erythromycin. At an
OD at 600 nm of 0.4 to 0.6, cultures were centrifuged at 5,000  g for 5
min and bacterial pellets resuspended in 1 ml of cold 50 mM potassium
monobasic phosphate buffer (pH 7.0) and homogenized in a Bead Beater
apparatus (BiospecProducts Inc., Bartlesville, OK, USA) with 0.1 mm
zirconia-silica beads (catalogue number 110791012; Biospec Products
Inc.). After 4 cycles of disruption (2 min) alternating with 2 min of incu-
bation on ice, samples were centrifuged (8,000  g, 10 min, 4°C), and the
supernatants were immediately used to determine enzymatic activities.
The protein concentration was determined with a Bio-Rad protein assay
kit (Bio-Rad Laboratories, Hercules, CA) based on method of Bradford
(17), using bovine serum albumin as a standard. CAT and SOD activities
were determined as previously described (18).
Preparation of bacterial suspensions and fermented milk for mouse
administration. Wild-type (WT) and recombinant streptococci (i.e., S.
thermophilus CRL 807:CAT and CRL 807:SOD) were grown in 10 ml of
LAPTg medium, washed, and resuspended in 1 ml of saline solution in
order to obtain a final concentration of 1  1010 CFU/ml. Coadministra-
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tion of S. thermophilus CRL 807:CAT and CRL 807:SOD (here called S.
thermophilus CRL 807:CAT/SOD) was performed by mixing each strain
suspension in a 1:1 ratio.
Before being used in the preparation of the fermented milk or admin-
istered to the mice, recombinant streptococcal cultures were washed twice
with 5 ml of saline solution (0.9% NaCl) in order to eliminate any remain-
ing traces of the antibiotic. The oral administration of 100 l of each
strain, strain mixture suspension, or saline solution was performed daily
using a catheter attached to a micropipette.
For fermented milk administration, reconstituted sterile nonfat milk
(Milkaut, Argentina) was inoculated with the WT, CAT, or SOD-produc-
ing streptococci strains described above at a concentration of 1% (vol/vol)
or with the S. thermophilus CRL 807:CAT/SOD mixture (0.5% each
strain). Milk was incubated statically for 16 h at 37°C.
The fermented milk prepared under these conditions contained an
average number of live bacteria of 1  1010 CFU/ml. Mice received the
fermented milk products or unfermented milk ad libitum. Fermented or
unfermented milk was prepared and changed daily (with checking that
the quality of the product was maintained), and the intake per mouse
was followed. Each animal in this trial drank approximately 3 ml of milk
per day.
Colitis induction and administration of bacteria. Induction of trini-
trobenzenesulfonic acid (TNBS) colitis was achieved essentially as previ-
ously described (5). Briefly, BALB/c mice (female, 5 weeks old) were fully
anesthetized with an intraperitoneal injection of ketamine hydrochloride
(Holliday-Scott S.A., Buenos Aires, Argentina) (100 g/g body weight)
mixed with xylazine hydrochloride (Rompun; Bayer, Division Sanidad
Animal, Buenos Aires, Argentina) (5 g/g body weight). Colitis was then
induced by intrarectal inoculation of TNBS solution (Sigma, St. Louis,
MO, USA) (2 mg/mouse) dissolved in 0.01 M phosphate-buffered saline
(PBS) (pH 7.4) and mixed with an equal volume of ethanol (50% etha-
nol), using a 4-cm-length catheter. Control mice (mock group) received
only PBS mixed with ethanol (without TNBS) using the same technique.
TNBS-treated mice were subdivided into 5 groups (n  6): (i) inflam-
mation control group (or TNBS group), (ii) mice receiving the S. thermo-
philus CRL 807 WT strain (WT group), (iii) mice receiving S. thermophi-
lus strain CRL 807 producing CAT (S. thermophilus CRL 807:CAT group),
(iv) mice receiving S. thermophilus strain CRL 807 producing SOD (S.
thermophilus CRL 807:SOD group), and (v) mice receiving coadministra-
tion of both recombinant S. thermophilus CRL 807 strains producing CAT
and SOD (S. thermophilus CRL 807:CAT/SOD group). LAB were admin-
istered to mice one day before TNBS injection and for 3 consecutive days
after colitis induction as a suspension in a volume of 100 l of saline
solution using a gavage syringe or in the fermented milk ad libitum. TNBS
and mock groups received either 100 l of saline solution by gavage or
unfermented milk ad libitum.
All groups were fed ad libitum with balanced rodent diet and main-
tained in a room with a 12-h light/dark cycle at 18  2°C. Body weight and
animal mortality rates were controlled daily.
Assessment of colonic inflammation. Four days after TNBS injection,
3 mice per group were sacrificed. Large intestines and ceca were removed,
visually inspected for macroscopic evaluation, and prepared for histolog-
ical analysis using standard methods. Serial paraffin sections of 4 m were
made and stained with hematoxylin-eosin (HE) for light microscopy ex-
amination. Macroscopic lesions and extent of colonic damage and inflam-
mation were assessed using previously described grading systems (13).
The analyses were performed by two different scientists. High macro-
scopic or histological damage scores indicate increased damage in the
intestines. Microbial translocation to liver was determined essentially as
previously described (19). Briefly, the liver was aseptically removed,
weighed, and homogenized in 5.0 ml sterile 0.1% (wt/vol) peptone solu-
tion. Serial dilutions of the homogenate were plated in triplicate in MRS,
MacConkey, and LAPTg media to detect a wide range of microorganisms.
Bacterial growth was evaluated after incubation of the plates at 37°C for 48
to 72 h.
Enzyme activity in the intestinal contents was determined. Large in-
testines were washed with 500 l of cold 50 mM potassium monobasic
phosphate buffer (pH 7.0). The samples were centrifuged at 3,000  g and
4°C for 15 min, the supernatants were collected, and the pellet was resus-
pended in 500 l of cold 50 mM potassium monobasic phosphate buffer
and homogenized in a Bead Beater apparatus with 0.1-mm zirconia-silica
beads, as described above. CAT and SOD activities and protein concen-
tration in both the supernatant and pellet were determined as previously
described (18). Results were expressed as specific units for the enzymatic
activity from the addition of the results obtained for the supernatant and
the respective pellet.
Cytokine producer cells in the intestinal tissue samples were also an-
alyzed. IL-10- and IL-17-positive cells were detected by indirect immuno-
fluorescence following the technique described above.
Statistical analyses. The in vitro analyses were performed in triplicate.
For animal experiments, 3 mice of each group (from a group of 6 animals
[see above]) were sacrificed and samples collected. The experimental pro-
tocol was performed three times (no interactions between these 3 inde-
pendent trials were observed), and the results (from the 3 trials) were
analyzed together (n  9). Statistical analyses were performed using
MINITAB 15 software. A factorial design (replicates-treatment) was used
for the experiments. Comparisons were done with an analysis of variance
(ANOVA) general linear model followed by Tukey’s post hoc test, and
unless otherwise specified, a P value of 	0.05 was considered significant.
RESULTS
Cytokine profiles induced by preselected strains of lactobacilli
and streptococci in vitro. As shown in Fig. 1A, cocultures of
PBMC with L. delbrueckii subsp. bulgaricus CRL 887, S. thermo-
philus CRL 806, and S. thermophilus CRL 807 resulted in the high-
est anti-inflammatory cytokine/proinflammatory cytokine (IL-
10/IL-12) ratio (Fig. 1A). The cytokine profile was also studied
using murine intestinal PPMC, which are more closely related to
the in vivo site of action of the putative anti-inflammatory strains
in the model used further in this study, mice. Fermented milk with
each LAB was evaluated, and IFN- was selected as the proinflam-
matory cytokine because it would also be evaluated in the intesti-
nal fluids of mice. The highest IL-10/IFN- ratios were observed
in the supernatants obtained from cocultures with milk fermented
by L. delbrueckii subsp. bulgaricus CRL 864 or S. thermophilus CRL
807 (Fig. 1B). These ratios were even higher that the ones obtained
with yogurt (our anti-inflammatory control). We thus decided to
test in vivo the immunomodulatory effects of milk fermented by
these two strains.
In vivo effects of the potentially anti-inflammatory selected
strains. As shown in Fig. 2A, samples of large intestine fluids from
mice that received milk fermented by either L. delbrueckii subsp.
bulgaricus CRL 864 or S. thermophilus CRL 807 for 10 days showed
a significant increase (P 	 0.05) of the IL-10/IFN- ratio. IL-17
was evaluated as another inflammatory cytokine because of its
relation with intestinal inflammation. For this study, samples of
intestinal tissues were analyzed and showed a significant increase
(P 	 0.05) in the ratio of IL-10
 cells to IL-17
 cells in the mice
given fermented milk compared to control mice (Fig. 2B). No
significant difference was observed in the body weights of animals
fed with the fermented milk in comparison with control animals
that received unfermented milk (data not shown).
Determination of CAT and SOD in recombinant strepto-
cocci. The results obtained by PCR confirmed a single amplicon of
approximately 600 bp in S. thermophilus CRL 807 transformed
with the pIL253-mnkat plasmid (S. thermophilus CRL 807:CAT),
as was also observed in the positive-control L. casei BL23 harbor-
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ing the same plasmid. Similarly, an amplicon of approximately
1,200 bp was observed in S. thermophilus CRL 807 transformed
with the pIL253-sodA plasmid (S. thermophilus CRL 807:SOD), as
was observed in the positive-control L. casei BL23 harboring the
same plasmid. No amplification was observed for WT S. thermo-
philus CRL 807 (Fig. 3C). Furthermore, CAT (Fig. 3A) and SOD
(Fig. 3B) activities were detected in the S. thermophilus CRL 807:
CAT and CRL 807:SOD strains, respectively, confirming biologi-
cal activity of the antioxidant enzymes in recombinant strepto-
cocci.
Genetically engineered S. thermophilus CRL 807 producing
antioxidant enzymes reduces the severity of TNBS-induced
chronic colitis. As shown in Fig. 4, mice receiving S. thermophilus
CRL 807:CAT, S. thermophilus CRL 807:SOD, or a mixture of
these strains (S. thermophilus CRL 807:CAT/SOD) orally using a
gavage syringe showed a significant improvement in weight loss
(Fig. 4A), significantly lower macroscopic and histological dam-
age scores (Fig. 4C), and a significantly lower liver microbial trans-
location (Fig. 4E) than TNBS control mice (P 	 0.05). Similar
results were observed when animals were fed ad libitum with milk
fermented by S. thermophilus CRL 807:CAT, CRL 807:SOD, or
both strains (S. thermophilus CRL 807:CAT/SOD) (Fig. 4B, D, and
F). Animals receiving the WT strain also showed significantly (P 	
0.05) lower macroscopic and microscopic damage scores (Fig. 4C
and D) and a lower liver microbial translocation than the TNBS
group (Fig. 4E).
Strikingly, animals that received coadministration of CAT-
and SOD-producing strains showed the lowest mortality rates
(data not shown). Considering the three independent trials to-
gether, until day 4 no deaths were observed when the strains were
coadministered as a bacterial suspension, and only 7% mortality
was observed in the group given the strains in fermented milk,
compared to mortalities of between 16% and 33% in the other test
groups and 50% in the TNBS group (data not shown). The mix-
FIG 1 Cytokine profile after coincubation of LAB with primary cultures of mononuclear cells. (A) IL-10 and IL-12 cytokines were quantified by ELISA after
coincubation of the different LAB with PBMC for 24 h, and IL-10/IL-12 ratios were determined; PBS was used a negative control. (B) IL-10 and IFN- cytokines
were quantified by ELISA after coincubation of each individual strain grown in milk, yogurt (positive control), or unfermented milk (negative control) with
Peyer’s patch mononuclear cells for 24 h, and IL-10/IFN- ratios were determined. Results are expressed as means  standard deviation (SD). Means with
asterisks differ significantly from control values (*, P 	 0.05; **, P 	 0.01).
FIG 2 Evaluation of anti-inflammatory potential effects of selected lactobacilli and streptococci in vivo. The ratio of anti-inflammatory cytokines to proinflam-
matory cytokines induced in large intestine fluids (A) or cells in the intestinal tissues (B) of mice fed with unfermented milk (negative control) or with milk
fermented by S. thermophilus CRL 807 or L. delbrueckii subsp. bulgaricus CRL 864 were determined. Results are expressed as means of  SD (n  9). Means with
asterisks differ significantly from control values (*, P 	 0.01).
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ture of recombinant streptococci was also administered with L.
delbrueckii subsp. bulgaricus CRL 864 (the other strain selected on
the basis of anti-inflammatory potential) and analyzed in the IBD
model; however, no additional benefits were observed compared
to those with the mixture of antioxidant enzyme-producing strep-
tococci (data not shown).
The increase in the antioxidant enzyme activities was related to
the improved anti-inflammatory effect exerted by the genetically
engineered S. thermophilus CRL 807 in the colitis model. Mice that
received the S. thermophilus CRL 807:CAT strain as a suspension
orally administered using a gavage syringe or ad libitum in milk
fermented by this strain had significantly increased catalase activ-
ity in their intestinal samples (Fig. 5A). The same was observed in
mice that received the S. thermophilus CRL 807:SOD strain (in
both feeding protocols), which significantly increased SOD activ-
ity in the large intestine samples, compared to those in the mock
and TNBS groups (Fig. 5B). Animals that received coadministra-
tion with CAT- and SOD-producing strains also showed signifi-
cant increases in both CAT and SOD activities in their intestines
compared to the other groups (Fig. 5A and B).
A mucosal decrease in IL-17-producing cells correlates with
the protective effects of recombinant S. thermophilus CRL 807
producing antioxidant enzymes. Mice that received the CRL 807
WT strain or the antioxidant enzyme-expressing strains had sig-
nificantly decreased (P 	 0.05) numbers of IL-17-producing cells
in the large intestines compared to those in the mice from TNBS
group (Fig. 6A), showing values similar to those in the mock
group. IL-10-producing cells increased significantly in all the mice
inoculated with TNBS, compared to the mock group (Fig. 6B);
thus, the ratio of IL-10
 cells to IL-17
 cells increased significantly
in mice given any bacterial supplementation, compared to the
inflammation control (TNBS group) (Fig. 6C). Remarkably, this
ratio was significantly increased in some groups of mice that re-
ceived the antioxidant-expressing strains compared to the mock
mice.
DISCUSSION
In this study, two strains (S. thermophilus CRL 807 and L. del-
brueckii subsp. bulgaricus CRL 864) from a pool of LAB from the
CERELA Culture Collection present in a yogurt, with proved anti-
inflammatory properties in an IBD model in mice (5), were se-
lected for their immunomodulatory potentials. The in vitro assays
demonstrated that these strains showed elevated IL-10/IL-12 and
IL-10/IFN- ratios in coculture with human PBMC and mouse
mononuclear cells isolated from Peyer’s patches (PPMC), respec-
tively. In this sense, previous in vitro trials using human PBMC
have allowed a preliminary classification of candidate beneficial
strains according to their immunomodulatory capacities (20). Cy-
tokine responses were also evaluated using cocultures of LAB with
PPMC of healthy mice because they may have a higher correlation
with the immunomodulatory effects expected in vivo in the IBD
mouse model, since it is known that PPs are of great importance in
the immune response at the mucosal level (21). In this assay, the
strains were grown in milk because the selected fermented milk
FIG 3 Detection of enzymatic activity and confirmation of recombinant streptococci. (A and B) Catalase (A) or superoxide dismutase (B) specific to WT S.
thermophilus CRL 807, CRL807:CAT (S. thermophilus CRL 807 transformed with the pIL253-mnkat plasmid) or S. thermophilus CRL 807:SOD (S. thermophilus
CRL 807 transformed with the pIL253-sodA plasmid) grown in LAPTg medium is expressed as enzymatic units (U) per mg of proteins and compared to the
enzymatic activity of L. casei BL23 harboring the same plasmid (L. casei BL23:CAT and BL23:SOD). The control is the culture medium. Results are expressed as
means  SD. Means without a common letter differ significantly (P 	 0.05). (C) PCR confirming single bands of approximately 600 and 1,200 bp that correspond
to the CAT and SOD enzymes, respectively, in the recombinant S. thermophilus CRL 807 (807:CAT and 807:SOD) and in the L. casei BL23 positive controls
harboring the same plasmid (BL23:CAT and BL23:SOD). No amplification was observed in the WT strains.
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FIG 4 Effects of recombinant streptococci expressing antioxidant enzymes on TNBS-induced inflammation in mice. The body weight percentage (A and B),
macro- and microscopic damage scores (C and D), and liver microbial translocation (E and F) were evaluated in mice from the mock group, mice from the TNBS
group, and mice that received the WT (S. thermophilus CRL 807 WT), S. thermophilus CRL 807:CAT (S. thermophilus CRL807 transformed with the pIL253-
mnkat plasmid), S. thermophilus CRL 807:SOD (S. thermophilus CRL 807 transformed with the pIL253-sodA plasmid), or S. thermophilus CRL 807:CAT/SOD
(coadministration of both recombinant streptococci) in suspension (A, C, and D) or in fermented milk (B, D, and F). Body weight was measured from the day
of TNBS inoculation up to 4 days after TNBS inoculation and they is represented as a percentage of the initial mouse body weight. Microscopic (black bars) and
macroscopic (gray bars) damage scores correspond to samples taken 4 days after TNBS inoculation. Each value represents the mean  SD (n  9). Microbial
growth in MacConkey, MRS, or LAPTg of liver samples obtained from different groups was evaluated. Results are expressed as means  SD of the log CFU/g liver.
Means for each value without a common letter differ significantly (P 	 0.05).
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would afterwards be evaluated in vivo. It is known that IL-12 plays
a major role in IBD by inducing lymphocytes to produce IFN-, so
IFN- in the supernatant from PPMC was evaluated because of
the predominance of lymphocytes in these isolated cells. Accord-
ing to these results, and considering the complexity of the intesti-
nal environment, the selected S. thermophilus CRL 807 and L.
delbrueckii subsp. bulgaricus CRL 864 were also analyzed in vivo by
evaluating the cytokine pattern in the intestinal fluids and tissues
of healthy mice fed with milk fermented by these LAB, demon-
strating a good correlation between in vitro and in vivo results (Fig.
1 and 2).
Several studies have confirmed the role of ROS in inflamma-
tion and the importance of antioxidant enzymes as a new
treatment approach for IBD (22–24). Carroll et al. reported that
treatment with SOD-producing Lactobacillus gasseri reduced in-
flammation in IL-10 knockout mice (8). Han et al. showed that
FIG 5 Enzymatic activity in the large intestine contents. CAT (A) and SOD (B) specific activities were determined in the intestinal contents of mice from the
mock group, mice from the TNBS group, and mice that received the WT (S. thermophilus CRL 807 WT), S. thermophilus CRL 807:CAT (S. thermophilus CRL
807transformed with the pIL253-mnkat plasmid), S. thermophilus CRL 807:SOD (S. thermophilus CRL 807 transformed with the pIL253-sodA plasmid), or S.
thermophilus CRL 807:CAT/SOD (coadministration of both recombinant streptococci) in suspension (white bars) or in fermented milk (gray bars). The results
are expressed as the means of the enzymatic units (EU) per mg of protein. * and #, significantly different from the mock or TNBS group, respectively (P 	 0.01).
FIG 6 IL-17- and IL-10-producing cells in the large intestine tissues. (A and B) IL-17 (A)- and IL-10 (B)-positive cells were evaluated by immunofluorescence
in mice from the mock group, mice from the TNBS group, and mice that received the WT (S. thermophilus CRL 807 WT), S. thermophilus CRL807:CAT (S.
thermophilus CRL807 transformed with the pIL253-mnkat plasmid), S. thermophilus CRL 807:SOD (S. thermophilus CRL 807 transformed with the pIL253-sodA
plasmid), or S. thermophilus CRL 807:CAT/SOD (coadministration of both recombinant streptococci) in suspension (black bars) or in fermented milk (gray
bars). The results are expressed as the means of the total number of positive cells counted in 10 fields at a magnification of 1,000. (C) Ratio between the number
of IL-10
 cells and the number of IL-17
 cells for each group. Data correspond to the means  SD (n  9). Means for each value without a common letter differ
significantly (P 	 0.01).
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administration of SOD-producing Lactobacillus lactis and Lacto-
bacillus plantarum diminished inflammation in a rat TNBS-in-
duced colitis model (9).
Recently, our group also reported that oral administration of
CAT- and SOD-producing L. casei BL23 was capable of reducing
colon damage scores in DSS-induced (10, 25) as well as TNBS-
induced (18) colitis mouse models. However, the most remark-
able effect of these strains was through their antioxidant mecha-
nisms and not through an immunomodulating mechanism (18).
Considering these previous results, the LAB selected for their
anti-inflammatory potential in this study were subjected to differ-
ent transformation protocols to introduce the antioxidant enzyme
genes into them. After many attempts, transformation of L. del-
brueckii subsp. bulgaricus CRL 864 was not possible, and we con-
tinued with the transformation of the selected streptococcal
strain. This difficulty has previously been encountered with other
L. delbrueckii subsp. bulgaricus strains and has been explained by
the presence of different restriction modification systems in their
genomes (26).
It is important to note that mnkat and sodA genes used in the
present study were cloned from L. plantarum ATCC 14432 and
Lactococcus lactis MG1363, respectively, which are also generally
recognized as safe (GRAS) microorganisms. Even though native
strains of S. thermophilus have also been reported to possess the
sodA gene (27), the S. thermophilus CRL 807 strain did not possess
SOD activity or the presence of this gene (Fig. 3), but since the
complete genome of this strain has not been determined, we can-
not discard the possibility that a sod gene might be present in this
strain and that the PCR parameters were not appropriate to show
it (10, 16). Due to the fact that S. thermophilus lacks the enzymes to
catalyze the reaction that detoxifies H2O2 into H2O and O2, such
as catalase, Fu et al. (33) have also recently developed an S. ther-
mophilus strain that produces heterologous catalase (encoded by
katE) from L. brevis ATCC 367. Interestingly, in that work it was
shown that KatE expression in S. thermophilus ST5 was beneficial
to L. delbrueckii subsp. bulgaricus ATCC 11842 cocultured in milk,
which confirms the functionality of this enzyme on this particular
food matrix. In contrast to that previous report, our work did not
show any additional benefits with the mixture of CAT- and/or
SOD-producing S. thermophilus CRL 807 with L. delbrueckii
subsp. bulgaricus CRL 864 (WT strain) compared to the mixture
of antioxidant enzyme-producing streptococci.
Finally, the anti-inflammatory potentials of the recombinant
streptococci were analyzed in vivo. Both protocols for administra-
tion (as a bacterial suspension by gavage or as fermented milk ad
libitum) of the antioxidant enzyme-producing S. thermophilus
strains used in this study decreased the severity of the inflamma-
tion, with less body weight loss, lower macroscopic and histolog-
ical damage scores in the large intestine, and a decrease of bacterial
translocation to liver, compared to the inflammation control (Fig.
4). These beneficial modifications were even increased compared
to those in the mice that received the WT strain. The remarkable
decrease in the mortality observed in mice receiving coadminis-
tration of CAT- and SOD-producing streptococci is of particular
interest. We hypothesize that the increased survival of these ani-
mals might be related to a more efficient reduction of ROS in the
presence of both enzymes (CAT and SOD), conferring a higher
antioxidant protection. Moreover, in a recent study it has been
shown that an anti-inflammatory strain of L. rhamnosus CNCMI-
3690 protected against oxidative stress and increased the life span
in Caenorhabditis elegans through a differential expression of the
DAF-16/insulin-like pathway (28). It is also important to note
that in both protocols of administration, WT S. thermophilus CRL
807 also decreased the severity of the inflammation compared to
that in the TNBS control group, corroborating the innate anti-
inflammatory potential of this strain selected by in vitro and in vivo
assays. In fact, a significant increase in the number of IL-10-pro-
ducing cells was observed in the large intestines of mice receiving
WT S. thermophilus (Fig. 5A); however, the elevated anti-inflam-
matory/proinflammatory cytokine-producing cell ratio was
maintained or even increased in those animals that received the
transforming strains, confirming an additive effect (their anti-
oxidant activities) in these mice (Fig. 5C).
To our knowledge this is the first time that an enhancement of
the anti-inflammatory activity has been achieved for an immuno-
modulatory strain of S. thermophilus by conferring on it the ca-
pacity to produce antioxidant enzymes. Our findings suggest that
LAB strains that are able to modulate immune responses and that
also express antioxidant enzymes could be useful in the develop-
ment of novel therapeutic products that prevent IBD. Although
genetically engineered strains are normally used to demonstrate a
“proof of concept,” some human clinical trials using modified
lactic acid bacteria have already been performed without any sig-
nificant negative side effects on the host: a phase 1 trial that eval-
uated the safety of a strain of L. lactis expressing human IL-10 for
the treatment of Crohn’s disease (29) and, more recently, a phase
1b study that evaluated a recombinant L. lactis strain secreting the
mucosal protectant human trefoil factor 1 (30). These studies set
the precedent for the clinical use of engineered probiotic micro-
organisms as potential treatment options.
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